VivoSeq
Other

Excretion

0

Pipeline Programs↗

2

Active Trials↗

7

Companies Involved↗

Excretion is an early-stage landscape with 0 programs across 7 companies. The most active players are AstraZeneca, GSK, Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

89/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalM

Merz Pharmaceuticals GmbH

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

34

clinical trials

Completed25 · 74%
Unknown status4 · 12%
Terminated2 · 6%
Recruiting2 · 6%
Withdrawn1 · 3%

Clinical Trials

Trial Activity

34 trials

Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants
Recruiting·Vertex Pharmaceuticals logoVertex Pharmaceuticals·Phase 1·NCT07378865·12 enrolled
Drug Excretion in Breast Milk
Recruiting·UUniversity of Washington·Phase 4·NCT06056583·50 enrolled
Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion
Completed·LLandspitali University Hospital·Phase 4·NCT02752633·9 enrolled
Serum Pharmacokinetic Disposition and Urinary Excretion of Albendazole
Completed·UUniversidad Nacional de Salta·Phase 1·NCT03192449·8 enrolled
A Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719
Completed·GSK logoGSK·Phase 1·NCT01362257·6 enrolled
Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin
Completed·—·Phase 4·NCT02791035·100 enrolled
Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects
Completed·Sanofi logoSanofi·Phase 1·NCT04171310·6 enrolled
To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]GW856553 in Healthy Adult Males
Completed·GSK logoGSK·Phase 1·NCT00599612·6 enrolled
A Study of the Excretion Balance of Radiocarbon and the Pharmacokinetics and Metabolic Profile of TRO19622 (Olesoxime)
Completed·Roche logoRoche·Phase 1·NCT02835976·6 enrolled
Exparel PK and Breast Milk Excretion
Completed·UUniversity of Minnesota·N/A·NCT03526419·30 enrolled
Excretion of Radiolabelled AZD0837
Completed·AstraZeneca logoAstraZeneca·Phase 1·NCT00812643·8 enrolled
Study of Excretion Balance and Pharmacokinetics of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal or Permanently Sterile Female Subjects
Completed·Sanofi logoSanofi·Phase 1·NCT03681158·5 enrolled
Changes in the Renal Excretion of Neramexane by Acidification of Urinary pH Study With and Without Application of a Urinary pH Acidification Regimen
Completed·MMerz Pharmaceuticals GmbH·Phase 1·NCT00972127
Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066
Completed·AstraZeneca logoAstraZeneca·Phase 1·NCT00829088·6 enrolled
Effect of Ketoconazole Inhibition of CYP3A on Urinary Excretion of Docetaxel
Completed·NNational University Hospital, Singapore·Phase 2·NCT00697437·10 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)